UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 303

Sortiert nach

Immune biomarkers of response to immune-checkpoint inhibitors in head and neck squamous cell carcinoma

Annals of oncology, 2019-01, Vol.30 (1), p.57-67

2019

Volltextzugriff (PDF)

Impact of tumor HPV status on outcome in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck receiving chemotherapy with or without cetuximab: retrospective analysis of the phase III EXTREME trial

Annals of oncology, 2014-04, Vol.25 (4), p.801-807

2014

Volltextzugriff (PDF)

Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study

Annals of oncology, 2020-07, Vol.31 (7), p.942-950

2020

Volltextzugriff (PDF)

KEYNOTE-048: Phase III study of first-line pembrolizumab (P) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC)

Annals of oncology, 2018-10, Vol.29, p.viii729-viii729

2018

Volltextzugriff (PDF)

SEOM clinical guidelines for the treatment of head and neck cancer (2020)

Clinical & translational oncology, 2021-05, Vol.23 (5), p.913-921

2021

Volltextzugriff (PDF)

Nutritional changes in patients with locally advanced head and neck cancer during treatment

Oral oncology, 2017-08, Vol.71, p.67-74

2017

Volltextzugriff (PDF)

Consensus guidelines for the management of radiation dermatitis and coexisting acne-like rash in patients receiving radiotherapy plus EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck

Annals of oncology, 2008-01, Vol.19 (1), p.142-149

2008

Volltextzugriff (PDF)

Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study

Annals of oncology, 2011-05, Vol.22 (5), p.1078-1087

2011

Volltextzugriff (PDF)

Comments on “Off-label despite high-level evidence: a clinical practice review of commonly used off-patent cancer medicines”

ESMO open, 2023-06, Vol.8 (3), p.101212-101212, Article 101212

2023

Volltextzugriff (PDF)

Cisplatin, 5-fluorouracil, and cetuximab (PFE) with or without cilengitide in recurrent/metastatic squamous cell carcinoma of the head and neck: results of the randomized phase I/II ADVANTAGE trial (phase II part)

Annals of oncology, 2014-03, Vol.25 (3), p.682-688

2014

Volltextzugriff (PDF)

Human papillomavirus-related oropharyngeal cancer

Annals of oncology, 2017-10, Vol.28 (10), p.2386-2398

2017

Volltextzugriff (PDF)

Randomized placebo-controlled phase II trial of high-dose melatonin mucoadhesive oral gel for the prevention and treatment of oral mucositis in patients with head and neck cancer undergoing radiation therapy concurrent with systemic treatment

Clinical & translational oncology, 2021-09, Vol.23 (9), p.1801-1810

2021

Volltextzugriff (PDF)

Adjuvant therapy with cetuximab for locally advanced squamous cell carcinoma of the oropharynx: results from a randomized, phase II prospective trial

Annals of oncology, 2013-02, Vol.24 (2), p.448-453

2013

Volltextzugriff (PDF)

The potential role of imaging techniques in avoiding neck dissection during salvage surgery after head and neck carcinoma treated with bioradiotherapy

Journal of laryngology and otology, 2021-11, Vol.135 (11), p.970-975

2021

Volltextzugriff (PDF)

SEOM clinical guideline in nasopharynx cancer (2017)

Clinical & translational oncology, 2018-01, Vol.20 (1), p.84-88

2018

Volltextzugriff (PDF)

Dasatinib worsens the effect of cetuximab in combination with fractionated radiotherapy in FaDu- and A431-derived xenografted tumours

British journal of cancer, 2014-09, Vol.111 (7), p.1310-1318

2014

Volltextzugriff (PDF)

Bloodstream infection in patients with head and neck cancer: a major challenge in the cetuximab era

Clinical & translational oncology, 2019-02, Vol.21 (2), p.187-196

2019

Volltextzugriff (PDF)

A phase Ib/II study (SCORES) of durvalumab (D) plus danvatirsen (DAN; AZD9150) or AZD5069 (CX2i) in advanced solid malignancies and recurrent/metastatic head and neck squamous cell carcinoma (RM-HNSCC): Updated results

Annals of oncology, 2018-10, Vol.29, p.viii372-viii372

2018

Volltextzugriff (PDF)

Correction to: SEOM clinical guidelines for the treatment of head and neck cancer (2020)

Clinical & translational oncology, 2021-05, Vol.23 (5), p.1001-1001

2021

Volltextzugriff (PDF)

Phase I II trial of cilengitide with cetuximab, cisplatin and 5-fluorouracil in recurrent and or metastatic squamous cell cancer of the head and neck: findings of the phase I part

British journal of cancer, 2011-05, Vol.104 (11), p.1691-1696

2011

Volltextzugriff (PDF)

Epidemiology of human papillomavirus-related oropharyngeal cancer in a classically low-burden region of southern Europe

Scientific reports, 2020-08, Vol.10 (1), p.13219-13219, Article 13219

2020

Volltextzugriff (PDF)

LBA36 Nivolumab (N) + ipilimumab (I) vs EXTREME as first-line (1L) treatment (tx) for recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Final results of CheckMate 651

Annals of oncology, 2021-09, Vol.32, p.S1310-S1311

2021

Volltextzugriff (PDF)

SUN-P091: Evolution of Nutritional Status in Locally Advanced Head and Neck (LAHNC) Patients Treated with Bioradiotherapy (BRT)

Clinical nutrition (Edinburgh, Scotland), 2016-09, Vol.35, p.S78-S78

2016

Volltextzugriff (PDF)

PO-091: TPExtreme randomized trial: Docetaxel-Platinum(P)-Cetuximab(C) versus 5FU-P-C in recurrent/metastatic HNSCC

Radiotherapy and oncology, 2015-02, Vol.114, p.46-46

2015

Volltextzugriff (PDF)

Multidisciplinary management of head and neck cancer: First expert consensus using Delphi methodology from the Spanish Society for Head and Neck Cancer (part 2)

Oral oncology, 2017-07, Vol.70, p.65-72

2017

Volltextzugriff (PDF)

1 – 25 von 303

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(293)
Mit Volltextzugriff
(287)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(118)
Life Sciences & Biomedicine
(109)
Humans
(84)
Female
(65)
Biological And Medical Sciences
(55)
Oncology
(51)
Male
(48)
Medical Sciences
(46)
Middle Aged
(45)
Adult
(40)
Aged
(34)
Tumors
(25)
Animals
(22)
Pharmacology. Drug Treatments
(22)
Pharmacology & Pharmacy
(20)
Hematology, Oncology And Palliative Medicine
(18)
Medicine
(16)
Plant Sciences
(16)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(15)
Cetuximab
(15)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Immune biomarkers of response to immune-checkpoint inhibitors in head and neck squamous cell carcinoma

Impact of tumor HPV status on outcome in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck receiving chemotherapy with or without cetuximab: retrospective analysis of the phase III EXTREME trial

Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study

KEYNOTE-048: Phase III study of first-line pembrolizumab (P) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC)

SEOM clinical guidelines for the treatment of head and neck cancer (2020)

Nutritional changes in patients with locally advanced head and neck cancer during treatment

Consensus guidelines for the management of radiation dermatitis and coexisting acne-like rash in patients receiving radiotherapy plus EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck

Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study

Comments on “Off-label despite high-level evidence: a clinical practice review of commonly used off-patent cancer medicines”

Cisplatin, 5-fluorouracil, and cetuximab (PFE) with or without cilengitide in recurrent/metastatic squamous cell carcinoma of the head and neck: results of the randomized phase I/II ADVANTAGE trial (phase II part)

Human papillomavirus-related oropharyngeal cancer

Randomized placebo-controlled phase II trial of high-dose melatonin mucoadhesive oral gel for the prevention and treatment of oral mucositis in patients with head and neck cancer undergoing radiation therapy concurrent with systemic treatment

Adjuvant therapy with cetuximab for locally advanced squamous cell carcinoma of the oropharynx: results from a randomized, phase II prospective trial

The potential role of imaging techniques in avoiding neck dissection during salvage surgery after head and neck carcinoma treated with bioradiotherapy

SEOM clinical guideline in nasopharynx cancer (2017)

Dasatinib worsens the effect of cetuximab in combination with fractionated radiotherapy in FaDu- and A431-derived xenografted tumours

Bloodstream infection in patients with head and neck cancer: a major challenge in the cetuximab era

A phase Ib/II study (SCORES) of durvalumab (D) plus danvatirsen (DAN; AZD9150) or AZD5069 (CX2i) in advanced solid malignancies and recurrent/metastatic head and neck squamous cell carcinoma (RM-HNSCC): Updated results

Correction to: SEOM clinical guidelines for the treatment of head and neck cancer (2020)

Phase I II trial of cilengitide with cetuximab, cisplatin and 5-fluorouracil in recurrent and or metastatic squamous cell cancer of the head and neck: findings of the phase I part

Epidemiology of human papillomavirus-related oropharyngeal cancer in a classically low-burden region of southern Europe

LBA36 Nivolumab (N) + ipilimumab (I) vs EXTREME as first-line (1L) treatment (tx) for recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Final results of CheckMate 651

SUN-P091: Evolution of Nutritional Status in Locally Advanced Head and Neck (LAHNC) Patients Treated with Bioradiotherapy (BRT)

PO-091: TPExtreme randomized trial: Docetaxel-Platinum(P)-Cetuximab(C) versus 5FU-P-C in recurrent/metastatic HNSCC

Multidisciplinary management of head and neck cancer: First expert consensus using Delphi methodology from the Spanish Society for Head and Neck Cancer (part 2)

Suchergebnisse filtern